<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887519</url>
  </required_header>
  <id_info>
    <org_study_id>Brigatinib-5008</org_study_id>
    <nct_id>NCT04887519</nct_id>
  </id_info>
  <brief_title>A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Brigatinib (Alunbrig®) in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) in Argentina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are to assess the safety profile of brigatinib and the clinical&#xD;
      response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small&#xD;
      Cell Lung Cancer (NSCLC). Treatment with brigatinib and follow-up will be according to&#xD;
      routine clinical practice.&#xD;
&#xD;
      Study doctors will review the participants' medical records at the start of the study, then&#xD;
      at 12 and 24 weeks after treatment starts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational post-marketing surveillance study of brigatinib in&#xD;
      participants with advanced or metastatic NSCLC. This study will assess the safety, efficacy&#xD;
      and effectiveness of brigatinib for its approved indications in a routine clinical practice&#xD;
      setting under real world use.&#xD;
&#xD;
      The study will enroll approximately 37 participants. The data will be collected both&#xD;
      prospectively and/or retrospectively at the specialized centers and outpatient oncology&#xD;
      clinics and will be recorded by the investigator in the electronic Case Report Form (eCRF)&#xD;
      based on the routine medical care data that is collected in the medical records. All the&#xD;
      participants will be assigned to a single observational cohort:&#xD;
&#xD;
      • All Participants&#xD;
&#xD;
      This multi-center study will be conducted in Argentina. The overall duration of the study&#xD;
      will be approximately 52 weeks. Data collection will be based on routine visit after every 12&#xD;
      weeks from the start of treatment up to 24 weeks of follow up or death or cancer progression&#xD;
      or treatment discontinuation, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Adverse Events (AEs) of Special Interest</measure>
    <time_frame>Up to 24 week</time_frame>
    <description>AEs of special interest includes Pneumonitis, interstitial lung disease, including early onset pulmonary events or symptoms; Hypertension; Bradycardia; Drug interactions with strong or moderate CYP3A inhibitors and inducers; hepatic toxicity; Myopathy, including elevation of creatine phosphokinase rhabdomyolysis and cardiomyopathy; Pancreatitis including elevation of lipase and amylase; Macular degeneration, retinopathy and visual disturbances and Embryo-fetal toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More AEs</measure>
    <time_frame>Up to 24 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 24 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Non-serious Adverse Events (Non-SAEs)</measure>
    <time_frame>Up to 24 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 week</time_frame>
    <description>ORR will be evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). CR: defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System Objective Response Rate (CNS-ORR)</measure>
    <time_frame>Up to 24 week</time_frame>
    <description>CNS-ORR will be evaluated by the investigator judgement based on usual clinical practice guided by RECIST version1.1 in all participants with evaluable CNS metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From first administration of study drug to the date of disease progression or death due to any cause (up to 24 week)</time_frame>
    <description>PFS will be evaluated by treating physicians according to RECIST version 1.1. PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first administration of study drug to death (up to 24 week)</time_frame>
    <description>OS is defined as the time interval from the date of the first dose of the study treatment until death due to any cause.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Anaplastic Lymphoma Kinase</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <description>Participants with advanced or metastatic ALK positive NSCLC who have been prescribed with brigatinib in real-world will be observed both prospectively and/or retrospectively at the local clinical practice setting and data will be taken from medical records of the routine visit after every 12 weeks from the start of treatment up to 24 weeks of follow up or death or cancer progression or treatment discontinuation, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>This is a non-interventional study.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with a diagnosis of ALK positive metastatic NSCLC that are treated with&#xD;
        brigatinib.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. With either a diagnosis of ALK positive metastatic NSCLC previously treated with&#xD;
        crizotinib OR a diagnosis of ALK positive metastatic NSCLC previously not treated with an&#xD;
        ALK inhibitor. Have received at least one dose of brigatinib according to approved&#xD;
        indications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Note: There are no specific exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Gallego</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5491150523121</phone>
      <email>eslutsky@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ezequiel Hernan Slutsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5491162029944</phone>
      <email>naveiraaa@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Alejandro Martin Naveira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Itraliano de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5491161015217</phone>
      <email>pablo.perez@hospitalitaliano.org.ar</email>
    </contact>
    <investigator>
      <last_name>Pablo Jose Perez Mesa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Htal Maria Curie</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5491144097957</phone>
      <email>gamalcervelli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gabriela Malcervelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Fleming</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>54 911 6693 6669</phone>
      <email>claudiomartin17@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Claudio Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto FLENI</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>54911 54683717</phone>
      <email>amuggeri@fleni.org.ar</email>
    </contact>
    <investigator>
      <last_name>Alejandro Muggeri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Guemes</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>54911 40899407</phone>
      <email>manuelvilanova@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Vilanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Htal Italiano La Plata</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5492215117020</phone>
      <email>susimdq@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Susana Beruti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Soria</name>
      <address>
        <city>San Salvador de Jujuy</city>
        <state>Jujuy</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5493884881678</phone>
      <email>cristinainklemona@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Cristina Inklemona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5493415509422</phone>
      <email>geu2004@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Graciela Elvira Uranga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>549 2477638380</phone>
      <email>marquitosliguori@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcos Liguori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cordoba</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>549 3513 32-8966</phone>
      <email>cecivdiazz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cecilia Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Medico Diagnosis</name>
      <address>
        <city>San Luis</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>549 2664685988</phone>
      <email>fernandezleyes@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcelo Fernandez Leyes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private room</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>5493815000953</phone>
      <email>josezarba@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Jose Zarba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/60a4dea31f1122001e30a7c9</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

